Avivagen Announces Results From Its Annual General Meeting April 8, 2021
Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) announced that at its Annual General Meeting (AGM), shareholders supported all resolutions, including the election of directors and reappointment of McGovern Hurley LLP as auditor. Key voting results include Kym Anthony receiving 96.6%, Graham Burton 96.7%, Aubrey Dan 97.4%, David Hankinson 96.7%, Jeffrey Kraws 97.3%, and Paul Mesburis 97.4% of votes cast in favor. Avivagen develops health products for livestock and companion animals, leveraging its OxC-beta™ technology for non-antibiotic health support.
- Shareholders voted overwhelmingly in favor of all resolutions at the AGM, reflecting strong confidence in management.
- High approval rates for the re-elected directors, with percentages generally over 96%.
- None.
Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen” or the “Corporation”) announces that at the Corporation’s Annual General Meeting (AGM) held today the Corporation’s shareholders voted to support all of the resolutions that came before the meeting. The resolutions included the reappointment of McGovern Hurley LLP as Avivagen’s auditor and the election of directors.
The voting results in respect of the election of directors are detailed below:
Nominee |
% Of Votes Cast At The Meeting
|
% Of Votes Cast At The Meeting
|
Kym Anthony |
|
|
Graham Burton |
|
|
Aubrey Dan |
|
|
David Hankinson |
|
|
Jeffrey Kraws |
|
|
Paul Mesburis |
|
|
About Avivagen
Avivagen is a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications. By unlocking an overlooked facet of β-carotene activity, a path has been opened to safely and economically support immune function, thereby promoting general health and performance in animals. Avivagen is a public corporation traded on the TSX Venture Exchange under the symbol VIV and on the OTCQB in the U.S. under the symbol VIVXF, is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada. For more information, visit www.avivagen.com. The contents of the website are expressly not incorporated by reference in this press release.
About OxC-beta™ Technology and OxC-beta™ Livestock
Avivagen’s OxC-beta™ technology is derived from Avivagen discoveries about β-carotene and other carotenoids, compounds that give certain fruits and vegetables their bright colours. Through support of immune function the technology provides a non-antibiotic means of promoting health and growth. OxC-beta™ Livestock is a proprietary product shown to be an effective and economic alternative to the antibiotics commonly added to livestock feeds. The product is currently available for sale in the United States, Philippines, Taiwan, New Zealand, Thailand, Mexico, Australia, Brazil and Malaysia.
Avivagen’s OxC-beta™ Livestock product is safe, effective and could fulfill the global mandate to remove all in-feed antibiotics as growth promoters. Numerous international livestock trials with poultry and swine using OxC-beta™ Livestock have proven that the product performs as well as, and, sometimes, in some aspects, better than in-feed antibiotics.
Forward Looking Statements
This news release includes certain forward-looking statements that are based upon the current expectations of management. Forward-looking statements involve risks and uncertainties associated with the business of Avivagen Inc. and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions “aim”, “anticipate”, “appear”, “believe”, “consider”, “could”, “estimate”, “expect”, “if”, “intend”, “goal”, “hope”, “likely”, “may”, “plan”, “possibly”, “potentially”, “pursue”, “seem”, “should”, “whether”, “will”, “would” and similar expressions. Statements regarding the potential for OxC-beta™ Livestock to fulfill the global mandate to remove all in-feed antibiotics as growth promoters are forward looking statements. Forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. For instance, Avivagen’s products may not gain market acceptance or regulatory approval in new jurisdictions or for new applications and may not be widely accepted as a replacement for antibiotics in livestock feeds due to many factors, many of which are outside of Avivagen’s control. Except as required by law, Avivagen assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Copyright © 2021 Avivagen Inc. OxC-beta™ is a trademark of Avivagen Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210408005751/en/
FAQ
What were the results of Avivagen's AGM held on October 2023?
Who were elected as directors during Avivagen's AGM?
What is Avivagen's focus as a life sciences corporation?
What is the stock symbol for Avivagen?
